J&J Overhauls Executive Team With Departures, Spinoff Looming
- Four senior leaders promoted as top executives depart
- Top scientist’s duties will be shared in R&D, public health
This article is for subscribers only.
Johnson & Johnson expanded a leadership overhaul as the health-care giant prepares for its chief executive officer and top scientist to depart before spinning off its consumer business.
Mathai Mammen, head of research and development for the Janssen pharmaceutical unit, and Bill Hait, global head of external innovation, will be elevated to executive vice president roles. They will share the duties of retiring Chief Scientific Officer Paul Stoffels though neither will take his title.